These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 31613363)

  • 21. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
    Marty FM; Ostrosky-Zeichner L; Cornely OA; Mullane KM; Perfect JR; Thompson GR; Alangaden GJ; Brown JM; Fredricks DN; Heinz WJ; Herbrecht R; Klimko N; Klyasova G; Maertens JA; Melinkeri SR; Oren I; Pappas PG; Ráčil Z; Rahav G; Santos R; Schwartz S; Vehreschild JJ; Young JH; Chetchotisakd P; Jaruratanasirikul S; Kanj SS; Engelhardt M; Kaufhold A; Ito M; Lee M; Sasse C; Maher RM; Zeiher B; Vehreschild MJGT;
    Lancet Infect Dis; 2016 Jul; 16(7):828-837. PubMed ID: 26969258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Invasive aspergillosis in solid organ transplantation].
    Silva JT; Torre-Cisneros J; Aguado JM
    Rev Iberoam Micol; 2018; 35(4):206-209. PubMed ID: 30467000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
    Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
    Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.
    Guinea J; Bouza E
    Future Microbiol; 2008 Dec; 3(6):603-15. PubMed ID: 19072177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
    Ananda-Rajah MR; Kontoyiannis D
    Future Microbiol; 2015; 10(5):693-708. PubMed ID: 26000646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.
    Desai A; Kovanda L; Kowalski D; Lu Q; Townsend R; Bonate PL
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5483-91. PubMed ID: 27381396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world use-Isavuconazole at a large academic medical center.
    Hassouna H; Athans V; Brizendine KD
    Mycoses; 2019 Jun; 62(6):534-541. PubMed ID: 30851214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.
    Rybak JM; Marx KR; Nishimoto AT; Rogers PD
    Pharmacotherapy; 2015 Nov; 35(11):1037-51. PubMed ID: 26598096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom.
    Floros L; Pagliuca A; Taie AA; Weidlich D; Rita Capparella M; Georgallis M; Sung AH
    J Med Econ; 2020 Jan; 23(1):86-97. PubMed ID: 31262225
    [No Abstract]   [Full Text] [Related]  

  • 30. A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Stern A; Su Y; Lee YJ; Seo S; Shaffer B; Tamari R; Gyurkocza B; Barker J; Bogler Y; Giralt S; Perales MA; Papanicolaou GA
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1195-1202. PubMed ID: 32088367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis.
    Zhang J; Zhang Y; Wu D; Cao G; Hamed K; Desai A; Aram JA; Guo X; Fayyad R; Cornely OA
    Mycoses; 2021 Apr; 64(4):445-456. PubMed ID: 33355949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial.
    Horn D; Goff D; Khandelwal N; Spalding J; Azie N; Shi F; Franks B; Shorr AF
    J Med Econ; 2016 Jul; 19(7):728-34. PubMed ID: 26960060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug development challenges and strategies to address emerging and resistant fungal pathogens.
    McCarthy MW; Walsh TJ
    Expert Rev Anti Infect Ther; 2017 Jun; 15(6):577-584. PubMed ID: 28480775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.
    Kovanda LL; Maher R; Hope WW
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):887-97. PubMed ID: 27160418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis.
    Schwartz S; Reisman A; Troke PF
    Infection; 2011 Jun; 39(3):201-10. PubMed ID: 21512792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: A case report.
    Adamsick ML; Elshaboury RH; Gift T; Mansour MK; Kotton CN; Gandhi RG
    Transpl Infect Dis; 2019 Apr; 21(2):e13048. PubMed ID: 30636363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis.
    Cheng MP; Orejas JL; Arbona-Haddad E; Bold TD; Solomon IH; Chen K; Pandit A; Kusztos AE; Cummins KC; Liakos A; Marty FM; Koo S; Hammond SP
    Mycoses; 2020 Jan; 63(1):58-64. PubMed ID: 31587405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antifungal efficacy of isavuconazole and liposomal amphotericin B in a rabbit model of Exserohilum rostratum meningoencephalitis: A preclinical paradigm for management of CNS phaeohyphomycosis.
    Petraitis V; Petraitiene R; Katragkou A; Maung BBW; Moradi PW; Sussman-Straus GE; Naing E; Kovanda LL; Finkelman MA; Walsh TJ
    Med Mycol; 2021 Feb; 59(2):189-196. PubMed ID: 33313821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
    Miceli MH; Kauffman CA
    Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antifungal drugs: An updated review of central nervous system pharmacokinetics.
    Wirth F; Ishida K
    Mycoses; 2020 Oct; 63(10):1047-1059. PubMed ID: 32772402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.